… of death in COVID-19, this review aims to evaluate an alternative therapeutic strategy by
using the PI3Kδ inhibitor Idelalisib in association with Ebastine, which may successful inhibit the …

… It has been suggested that the PI3Kδ inhibitor idelalisib, alone or in … COVID-19. Accordingly,
ebastine in association with an antiviral is being investigated for the treatment of COVID-19. …

… Using therapeutic methods that inhibit harmful immune responses … COVID-19 disease. We
highlighted the potential contribution of PI3K/Akt/mTOR inhibitors in the treatment of COVID-19…

… These results suggests that COVID-19 disease severity is … inflammatory cytokines through
PI3K inhibition may prevent the … nemiralisib, an inhaled PI3Kδ-selective inhibitor that is under …

… (PI3Kδ/γ) inhibitor for treating relapsed or refractory CLL/SLL and FL. PI3Kδ/γ inhibitors
promote the formation of a pool of T-cells with a memory phenotype by inhibiting aerobic …

… time of the prevalence of coronavirus disease 2019 (COVID-19), … to PI3Kδ (A), PI3Kβ (B),
and NF-κB p65 (C). (D) 3D schematic diagram of active space binding of D-limonene and PI3Kδ…

… with an antiviral in the treatment of COVID-19 positive patients is underway (21). … COVID-19,
this review aims to evaluate an alternative therapeutic strategy by using the PI3Kd inhibitor …

… In particular, PI3Kδ isoform inhibitors are considered as a valuable approach for the treatment
of inflammatory lung diseases. Therefore, PI3Kδ inhibitors idelalisib and ebastine, which …

… in these cells to provide a rationale for how such inhibitors could modify clinical courses of
diseases, such as COVID-19. COVID-19 has major global impacts on health and economy, …

… Although PI3Kδ inhibitors have been used in the treatment of … revealing the potential of PI3Kδ
inhibitors for the treatment of … promising therapeutic strategy for COVID-19-induced ARDS, …